Genevive Hernandez

TL;DR: Data suggest that the anti-VEGF and anti-PD-L1 combination improves antigen-specific T-cell migration, and trafficking lymphocyte increases are observed in tumors following bevacizumab and combination treatment.

TL;DR: Treatment with BRAF and/or MEK inhibitors followed by addition of anti-PD-L1 in BRAF-mutant melanoma patients is safe and shows promising anti-tumor activity.

TL;DR: Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; AbbVie: consultants, membership on an entities' Board of directors or advisory Committees, Research funding, Speaker Bureau.

TL;DR: Atezolizumab plus cobimetinib had manageable safety and clinical activity irrespective of KRAS/BRAF status and potential synergistic activity was seen in mCRC, but this was not confirmed in a subsequent phase III study.

TL;DR: It is postulated that combining atezo (anti-PD-L1) with bev would augment anti-tumor immune responses, resulting in improved and more durable clinical benefit, and results from the first study of an anti-PD -L1 agent + VEGF-A blockade in MSI-high mCRC are reported.